MedTrace Logo

E-Health for Zero Infections - Facilitating Access to and Use of HIV Pre-Exposure Prophylaxis (PrEP) in the Netherlands

NCT05093036 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 469

Last updated 2024-12-13

No results posted yet for this study

Summary

Offering PrEP care online and reducing the frequency of monitoring may increase access to HIV PrEP. The objective of this study is to assess the non-inferiority of an internet-based HIV PrEP-service and reduced frequency of monitoring visits in comparison to standard-of-care at the Public Health Service in 4 regions in the Netherlands: Amsterdam, Rotterdam-Rijnmond, Haagland and Gelderland-Zuid.

Conditions

  • HIV Infections

Interventions

OTHER

Variations in PrEP care delivery at public health services

Variations on routine PrEP care at the Public Health Services in the Netherlands: online PrEP care and reduced frequency of monitoring

Sponsors & Collaborators

  • Public Health Service Rotterdam-Rijnmond

    collaborator UNKNOWN

  • Public Health Service Haaglanden

    collaborator UNKNOWN

  • Public Health Service Gelderland-Zuid

    collaborator UNKNOWN

  • The National Institute for STI and Aids Control in the Netherlands (Soa Aids Nederland)

    collaborator UNKNOWN

  • Stichting Aidsfonds

    collaborator UNKNOWN

  • DC Pharmacy of DC Klinieken

    collaborator UNKNOWN

  • Public Health Service of Amsterdam

    lead OTHER_GOV

Principal Investigators

  • Udi Davidovich, PhD · Public Health Service of Amsterdam

  • Maarten Schim van der Loeff · Public Health Service of Amsterdam

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-21
Primary Completion
2024-03-31
Completion
2024-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05093036 on ClinicalTrials.gov